semaglutide for kidney failure significantly reduces risk of major disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease Chronic Kidney Disease | Ozempic®

Lets start with benefit design, which is very unique in the Medicare program

Our GLP1 Insights Report dives into how were helping clients: Achieve lower costs through proactive formulary strategies Choose flexible plan designs that expand access without breaking budgets Take advantage of a proven clinical model that delivers strong, sustainable outcomes Download the Insights Report: To view or add a comment, sign in As GLP-1s become a table-stakes benefit, the real decision for 2026 isnt access

Kiss, who is also associate dean of clinical compliance at Weill Cornell

Semaglutide is administered via subcutaneous injection once per week using a pre-filled pen